Abbott Laboratories' Q3 comparable sales growth market reflects trader focus on the company's October 21 earnings release and its reaffirmed full-year 2026 guidance of 6.5% to 7.5% organic growth, which excludes foreign exchange and acquisition effects. Analyst consensus anticipates reported revenue near $12.9–13.0 billion, supported by a sharp Diagnostics rebound from the Exact Sciences acquisition and continued Medical Devices momentum in diabetes care, though Nutrition segment pressures and base effects may temper the comparable figure. Market-implied odds favor the 6%–8% band as the closest alignment with that guidance range, while higher outcomes price in potential upside from new product adoption and international volumes. Key swing factors include segment-level organic performance details and any revisions to forward expectations.